TerminatedNCT00857818
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolarity type I Who Have Metabolic Syndrome
Medication studyAges 18–65Canada
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Calgary and 13 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateApril 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 64
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00857818
- Official title
Show the full official title
A 16-Week, Randomized, Controlled Trial of the Effect of Aripiprazole Versus Standard of Care on Non-HDL Cholesterol Among Patients With Schizophrenia and Bipolar I Disorder Who Have Pre-existing Metabolic Syndrome
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Calgary · Pentincton · Vancouver
7 more locations
- Hamilton
- London
- Markham
- Mississauga
- Toronto
- Montreal
- Québec
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Aripiprazole and Oanzapine, risperidone, or quetiapine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
